TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma
Authors:
Open Access
- 1 February 2020
- journal article
- research article
- Published by Biomedical Research Press in Biomedical Research
- Vol. 41 (1) , 53-65
Abstract
Platinum-based adjuvant chemotherapy after complete resection has become a standard treatment for patients with stage II to IIIA non-small cell lung cancer; however, not all patients exhibit survival benefits. Therefore, the development of predictive biomarkers for selecting a subgroup of patients who may show improved survival after these treatments is important. Among the 42 proteins identified here using a proteomics analysis that were recognized by autoantibodies in pretreated sera from patients with lung adenocarcinoma who received platinum-based adjuvant chemotherapy, the tumor necrosis factor-receptor-associated protein 1 (TRAP1) was detected in patients with a short disease-free survival. TRAP1 expression was immunohistochemically analyzed in 64 patients with completely resected stage II and IIIA lung adenocarcinoma treated with platinum-based adjuvant chemotherapy. TRAP1 expression was significantly associated with higher p-TNM stage (P = 0.005) and lymph node metastasis (P = 0.017). Moreover, TRAP1 expression was significantly correlated with a shorter disease-free survival (P = 0.028). Furthermore, TRAP1-siRNA-treated LC-2/ad cells derived from lung adenocarcinoma exhibited significantly reduced proliferation and increased sensitivity to cisplatin. These results suggest that TRAP1 expression is a valuable biomarker for predicting the poor survival of platinum-based adjuvant chemotherapy in patients with resected lung adenocarcinoma.Keywords
This publication has 33 references indexed in Scilit:
- Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortiumMolecular Cancer, 2012
- TRAP-1, the mitochondrial Hsp90Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2012
- Global Targeting of Subcellular Heat Shock Protein-90 Networks for Therapy of GlioblastomaMolecular Cancer Therapeutics, 2010
- Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataThe Lancet, 2010
- Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin EvaluationJournal of Thoracic Oncology, 2010
- Cytoprotective Mitochondrial Chaperone TRAP-1 As a Novel Molecular Target in Localized and Metastatic Prostate CancerThe American Journal of Pathology, 2010
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Detection of tumor-specific autoantibodies in sera of patients with lung cancerLung Cancer, 2008
- Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancerBiochemical and Biophysical Research Communications, 2005
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003